Brian Stephenson
Equibles does not estimate personal net worth.
Get an email with a short summary when BridgeBio Pharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get BBIO alertsAbout Brian Stephenson
Brian Stephenson is recorded as CFO at BridgeBio Pharma, Inc. (BBIO) and CFO at Faeth Therapeutics, Inc. (FTH) since June 13, 2026. The newest filing on record that lists Brian Stephenson as CFO at BridgeBio Pharma, Inc. (BBIO) is dated April 24, 2026. Faeth Therapeutics, Inc. reported in an 8-K filed June 15, 2026 that Brian Stephenson was appointed Chief Financial Officer, effective June 13, 2026. The proxy statement of BridgeBio Pharma, Inc. reports total compensation of $684,661 for Brian Stephenson in fiscal 2025, including a base salary of $156,431. Disclosed compensation is on record for 8 fiscal years. BridgeBio Pharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Faeth Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Pharma, Inc. includes Neil Kumar (CEO and Board Member), Charles Homcy (Chairman and Board Member), Thomas Trimarchi (CFO and COO) and 7 others.
“Effective as of June 13, 2026, Brian Stephenson was appointed as the Company’s Chief Financial Officer and principal financial officer.”
Affiliation history
-
Current
2026-06-13–present
-
Current
Start not stated–present
Last confirmed April 24, 2026
-
Start not stated–2025-03-17
Company network
Leadership on record at BridgeBio Pharma, Inc.
- Neil Kumar CEO, Board Member
- Charles Homcy Chairman, Board Member
- Thomas Trimarchi CFO, COO
- Brian Stolz COO
- Brian C. Stephenson Chief Accounting Officer
- Ali J. Satvat Board Member
- Andrea Ellis Board Member
- Andrea J. Ellis Board Member
- Andrew W. Lo Board Member
- Douglas A. Dachille Board Member
Leadership on record at Faeth Therapeutics, Inc.
- Anand Parikh CEO, Chairman, COO, Board Member
- John Celebi CEO, Board Member
- William Ringo Chairman, Board Member
- Josiah Craver CFO, Chief Accounting Officer
- Christopher W. Gerry General Counsel, Board Member
- Adam Schayowitz Board Member
- Bob Holmen Board Member
- Karen Vousden, Ph.D. Board Member
- Kristian Humer Board Member
- Phillip B. Donenberg Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | BridgeBio Pharma, Inc. (BBIO) | Ph.D., CFA Former Chief Financial Officer | $156,431 | $684,661 |
| 2024 | BridgeBio Pharma, Inc. (BBIO) | Ph.D., CFA Former Chief Financial Officer | $661,046 | $5,663,687 |
| 2023 | BridgeBio Pharma, Inc. (BBIO) | Ph.D., CFA Former Chief Financial Officer | $650,000 | $6,651,996 |
| 2022 | BridgeBio Pharma, Inc. (BBIO) | Ph.D., CFA Former Chief Financial Officer | $650,000 | $2,957,392 |
| 2021 | BridgeBio Pharma, Inc. (BBIO) | Ph.D., CFA Chief Financial Officer | $600,000 | $8,677,297 |
| 2020 | BridgeBio Pharma, Inc. (BBIO) | Ph.D., CFA Chief Financial Officer | $550,000 | $4,163,933 |
| 2019 | BridgeBio Pharma, Inc. (BBIO) | Ph.D., CFA Chief Financial Officer | $420,000 | $4,198,967 |
| 2018 | BridgeBio Pharma, Inc. (BBIO) | Ph.D., CFA Chief Financial Officer | $74,375 | $2,347,115 |